X-Shining™ AST cefotaxime, Biosynth Patent WO 2021/176101
Ref. 3D-EX182070
| 1piece | 196,00 € |
Información del producto
Antibiotic resistance of pathogenic bacteria is a rising threat to human health world-wide. For treatment and prevention it is crucial to identify and track antibiotic resistant bacteria. X-ShiningTM AST Cefotaxime (AST stands for antibiotic susceptibility test) is an alternative test system to conventional, growth based AST tests with a read-out time of only 30 to 60 min. The test relies on the monitoring of released ATP in the absence and presence of the Cefotaxime at 20 µg/mL final assay concentration. ATP release is measured via luminescence signal generated by reaction of ATP with X-ShiningTM luciferase and D-luciferin. Product EX182070 is a lyophilisate containing all necessary components required for the assay and can be used immediately after reconstitution with ultrapure water. The antibiotic Cefotaxime interferes with cell wall synthesis, which leads to increased leakage of ATP within 30 to 60 min after exposing bacterial cells to nutrients and antibiotic. Thus, Cefotaxime sensitive bacteria exhibit a considerably increased luminescence (at least factor 10) in the presence of Cefotaxime relative to control assays without antibiotic, using product EX182068, X-ShiningTM Base Medium. By contrast, resistant strains which express carbapenemase do not show such a response, the ratio of luminescence with and without antibiotic remains below 3. Find out more about our innovative X-Shining range here X-Shining | Innovation | Cymit Quimica Carbosynth.
Propiedades químicas
Consulta técnica sobre: 3D-EX182070 X-Shining™ AST cefotaxime, Biosynth Patent WO 2021/176101
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
